Assessment of blood loss after vaginal delivery with the use of tranexamic acid in third stage of labour .

FIGO and WHO recommends the use of oxytocin as the first line uterotonic drug for the prevention of PPH. Intravenous oxytocin infusion alone is the recommended uterotonic drug for the treatment of PPH. Tranexamic acid is used in the treatment of PPH if oxytocin and other uterotonics fail to stop bleeding or if it is thought that blood loss may be partly due to trauma.

TXA is proven efficient in the treatment of PPH and has an advantage over oxytocin in decreasing blood loss in traumatic PPH as oxytocin can prevent blood loss in atonic PPH only. Also, TXA doesn’t require cold storage, easily available over the counter, doesn’t lead to volume overload in patients with heart disease, anaemia etc. So ,we are thinking to extend the use of TXA as a prophylactic agent for preventing PPH.

Oxytocin is used as a standard drug for preventing PPH. We will add a drug with different mechanism of action, TXA, with oxytocin to see whether the combination is more effective in preventing PPH. If proven more effective, TXA can be compared with oxytocin alone in preventing PPH.